IMMUNOCORE HOLDINGS PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.64 USD | -0.95% |
|
-8.86% | -37.69% |
| Sales 2024 * | 239M 305M | Sales 2025 * | 261M 333M | Capitalization | 1.69B 2.15B |
|---|---|---|---|---|---|
| Net income 2024 * | -80M -102M | Net income 2025 * | -95M -121M | EV / Sales 2024 * | 5.96 x |
| Net cash position 2024 * | 263M 336M | Net cash position 2025 * | 214M 273M | EV / Sales 2025 * | 5.64 x |
| P/E ratio 2024 * |
-22.3
x | P/E ratio 2025 * |
-18
x | Employees | 497 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 44.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Immunocore Holdings plc
More recommendations
More press releases
| 1 day | -0.55% | ||
| 1 week | -5.80% | ||
| Current month | -12.11% | ||
| 1 month | -28.52% | ||
| 3 months | -33.83% | ||
| 6 months | -18.12% | ||
| Current year | -36.99% |
1 week
41.11
49.05
1 month
41.0162.22
Current year
41.0176.98
1 year
41.0176.98
3 years
18.4376.98
5 years
18.4376.98
10 years
18.4376.98
| Managers | Title | Age | Since |
|---|---|---|---|
Bahija Jallal
CEO | Chief Executive Officer | 62 | 18-12-31 |
Brian DiDonato
DFI | Director of Finance/CFO | 57 | 20-03-31 |
John Trainer
COO | Chief Operating Officer | 50 | 23-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Perez
BRD | Director/Board Member | 59 | 19-08-31 |
John Bell
CHM | Chairman | 71 | 15-02-28 |
Bahija Jallal
CEO | Chief Executive Officer | 62 | 18-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.23% | 1,085 M€ | +9.49% | - | |
| 0.18% | 0 M€ | 0.00% | - | |
| 0.14% | 5 M€ | +17.05% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 42.57 | -1.11% | 181 332 |
| 24-06-05 | 43.05 | -0.60% | 758,245 |
| 24-06-04 | 43.31 | +1.33% | 1,753,046 |
| 24-06-03 | 42.74 | -12.74% | 3,011,928 |
| 24-05-31 | 48.98 | +4.86% | 1,184,594 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotes
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
33.72
GBP
Average target price
66.75
GBP
Spread / Average Target
+97.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -36.99% | 2.15B | |
| +42.69% | 749B | |
| +38.92% | 605B | |
| -6.87% | 351B | |
| +18.74% | 328B | |
| +6.76% | 292B | |
| +11.24% | 216B | |
| -2.54% | 214B | |
| +2.64% | 167B | |
| +6.72% | 165B |
- Stock Market
- Equities
- IMCR Stock
